Go Pro
→ A letter from Shannon Stansberry (From Porter & Company) (Ad)tc pixel Free ATOS Stock Alerts

Atossa Genetics (ATOS) Competitors

Atossa Genetics logo
$2.45 -0.04 (-1.61%)
As of 11:38 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

ATOS vs. ENTX, HRTX, LFVN, CYPH, and GANX

Should you buy Atossa Genetics stock or one of its competitors? MarketBeat compares Atossa Genetics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Atossa Genetics include Entera Bio (ENTX), Heron Therapeutics (HRTX), Lifevantage (LFVN), Cypherpunk Technologies (CYPH), and Gain Therapeutics (GANX). These companies are all part of the "pharmaceutical products" industry.

How does Atossa Genetics compare to Entera Bio?

Atossa Genetics (NASDAQ:ATOS) and Entera Bio (NASDAQ:ENTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership, earnings and profitability.

Atossa Genetics has a beta of 1.25, meaning that its stock price is 25% more volatile than the broader market. Comparatively, Entera Bio has a beta of 1.43, meaning that its stock price is 43% more volatile than the broader market.

Entera Bio has higher revenue and earnings than Atossa Genetics. Entera Bio is trading at a lower price-to-earnings ratio than Atossa Genetics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Atossa GeneticsN/AN/A-$34.77M-$3.21N/A
Entera Bio$40K2,409.05-$11.44M-$0.27N/A

12.7% of Atossa Genetics shares are held by institutional investors. Comparatively, 14.1% of Entera Bio shares are held by institutional investors. 9.8% of Atossa Genetics shares are held by company insiders. Comparatively, 10.6% of Entera Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Entera Bio had 1 more articles in the media than Atossa Genetics. MarketBeat recorded 2 mentions for Entera Bio and 1 mentions for Atossa Genetics. Entera Bio's average media sentiment score of 0.97 beat Atossa Genetics' score of 0.00 indicating that Entera Bio is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Atossa Genetics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Entera Bio
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Entera Bio's return on equity of -83.31% beat Atossa Genetics' return on equity.

Company Net Margins Return on Equity Return on Assets
Atossa GeneticsN/A -84.91% -72.36%
Entera Bio N/A -83.31%-70.83%

Atossa Genetics currently has a consensus price target of $20.33, suggesting a potential upside of 729.93%. Entera Bio has a consensus price target of $9.00, suggesting a potential upside of 360.36%. Given Atossa Genetics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Atossa Genetics is more favorable than Entera Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Atossa Genetics
2 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.20
Entera Bio
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Summary

Entera Bio beats Atossa Genetics on 10 of the 14 factors compared between the two stocks.

How does Atossa Genetics compare to Heron Therapeutics?

Heron Therapeutics (NASDAQ:HRTX) and Atossa Genetics (NASDAQ:ATOS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and dividends.

80.0% of Heron Therapeutics shares are owned by institutional investors. Comparatively, 12.7% of Atossa Genetics shares are owned by institutional investors. 6.1% of Heron Therapeutics shares are owned by company insiders. Comparatively, 9.8% of Atossa Genetics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Heron Therapeutics has a beta of 1.65, meaning that its stock price is 65% more volatile than the broader market. Comparatively, Atossa Genetics has a beta of 1.25, meaning that its stock price is 25% more volatile than the broader market.

Heron Therapeutics has higher revenue and earnings than Atossa Genetics. Heron Therapeutics is trading at a lower price-to-earnings ratio than Atossa Genetics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Heron Therapeutics$154.90M0.60-$20.19M-$0.18N/A
Atossa GeneticsN/AN/A-$34.77M-$3.21N/A

In the previous week, Atossa Genetics had 1 more articles in the media than Heron Therapeutics. MarketBeat recorded 1 mentions for Atossa Genetics and 0 mentions for Heron Therapeutics. Atossa Genetics' average media sentiment score of 0.00 beat Heron Therapeutics' score of -1.00 indicating that Atossa Genetics is being referred to more favorably in the news media.

Company Overall Sentiment
Heron Therapeutics Negative
Atossa Genetics Neutral

Atossa Genetics has a net margin of 0.00% compared to Heron Therapeutics' net margin of -20.53%. Atossa Genetics' return on equity of -84.91% beat Heron Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Heron Therapeutics-20.53% -7,747.30% -8.94%
Atossa Genetics N/A -84.91%-72.36%

Heron Therapeutics presently has a consensus price target of $2.50, suggesting a potential upside of 412.30%. Atossa Genetics has a consensus price target of $20.33, suggesting a potential upside of 729.93%. Given Atossa Genetics' stronger consensus rating and higher probable upside, analysts plainly believe Atossa Genetics is more favorable than Heron Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Heron Therapeutics
2 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.00
Atossa Genetics
2 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.20

Summary

Atossa Genetics beats Heron Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Atossa Genetics compare to Lifevantage?

Atossa Genetics (NASDAQ:ATOS) and Lifevantage (NASDAQ:LFVN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, earnings, valuation, media sentiment, profitability, analyst recommendations and dividends.

Atossa Genetics has a beta of 1.25, meaning that its share price is 25% more volatile than the broader market. Comparatively, Lifevantage has a beta of 0.73, meaning that its share price is 27% less volatile than the broader market.

In the previous week, Atossa Genetics and Atossa Genetics both had 1 articles in the media. Lifevantage's average media sentiment score of 1.05 beat Atossa Genetics' score of 0.00 indicating that Lifevantage is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Atossa Genetics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Lifevantage
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Lifevantage has a net margin of 2.94% compared to Atossa Genetics' net margin of 0.00%. Lifevantage's return on equity of 23.89% beat Atossa Genetics' return on equity.

Company Net Margins Return on Equity Return on Assets
Atossa GeneticsN/A -84.91% -72.36%
Lifevantage 2.94%23.89%12.47%

12.7% of Atossa Genetics shares are held by institutional investors. Comparatively, 35.3% of Lifevantage shares are held by institutional investors. 9.8% of Atossa Genetics shares are held by insiders. Comparatively, 22.0% of Lifevantage shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Atossa Genetics currently has a consensus price target of $20.33, indicating a potential upside of 729.93%. Lifevantage has a consensus price target of $5.00, indicating a potential downside of 19.90%. Given Atossa Genetics' stronger consensus rating and higher probable upside, analysts plainly believe Atossa Genetics is more favorable than Lifevantage.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Atossa Genetics
2 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.20
Lifevantage
0 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Lifevantage has higher revenue and earnings than Atossa Genetics. Atossa Genetics is trading at a lower price-to-earnings ratio than Lifevantage, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Atossa GeneticsN/AN/A-$34.77M-$3.21N/A
Lifevantage$228.53M0.34$9.81M$0.4513.87

Summary

Lifevantage beats Atossa Genetics on 10 of the 14 factors compared between the two stocks.

How does Atossa Genetics compare to Cypherpunk Technologies?

Atossa Genetics (NASDAQ:ATOS) and Cypherpunk Technologies (NASDAQ:CYPH) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, valuation, dividends, institutional ownership, earnings and media sentiment.

In the previous week, Atossa Genetics had 1 more articles in the media than Cypherpunk Technologies. MarketBeat recorded 1 mentions for Atossa Genetics and 0 mentions for Cypherpunk Technologies. Atossa Genetics' average media sentiment score of 0.00 equaled Cypherpunk Technologies'average media sentiment score.

Company Overall Sentiment
Atossa Genetics Neutral
Cypherpunk Technologies Neutral

Atossa Genetics presently has a consensus price target of $20.33, indicating a potential upside of 729.93%. Cypherpunk Technologies has a consensus price target of $0.90, indicating a potential upside of 18.36%. Given Atossa Genetics' higher possible upside, equities research analysts plainly believe Atossa Genetics is more favorable than Cypherpunk Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Atossa Genetics
2 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.20
Cypherpunk Technologies
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
2.50

Cypherpunk Technologies' return on equity of -48.33% beat Atossa Genetics' return on equity.

Company Net Margins Return on Equity Return on Assets
Atossa GeneticsN/A -84.91% -72.36%
Cypherpunk Technologies N/A -48.33%-42.21%

Atossa Genetics has a beta of 1.25, suggesting that its share price is 25% more volatile than the broader market. Comparatively, Cypherpunk Technologies has a beta of 0.07, suggesting that its share price is 93% less volatile than the broader market.

12.7% of Atossa Genetics shares are owned by institutional investors. Comparatively, 30.5% of Cypherpunk Technologies shares are owned by institutional investors. 9.8% of Atossa Genetics shares are owned by company insiders. Comparatively, 3.5% of Cypherpunk Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Cypherpunk Technologies is trading at a lower price-to-earnings ratio than Atossa Genetics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Atossa GeneticsN/AN/A-$34.77M-$3.21N/A
Cypherpunk TechnologiesN/AN/A$4.82M-$0.02N/A

Summary

Cypherpunk Technologies beats Atossa Genetics on 7 of the 13 factors compared between the two stocks.

How does Atossa Genetics compare to Gain Therapeutics?

Gain Therapeutics (NASDAQ:GANX) and Atossa Genetics (NASDAQ:ATOS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, media sentiment, analyst recommendations and dividends.

12.0% of Gain Therapeutics shares are owned by institutional investors. Comparatively, 12.7% of Atossa Genetics shares are owned by institutional investors. 4.2% of Gain Therapeutics shares are owned by insiders. Comparatively, 9.8% of Atossa Genetics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Gain Therapeutics had 2 more articles in the media than Atossa Genetics. MarketBeat recorded 3 mentions for Gain Therapeutics and 1 mentions for Atossa Genetics. Gain Therapeutics' average media sentiment score of 0.00 equaled Atossa Genetics'average media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Gain Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Atossa Genetics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Gain Therapeutics has higher revenue and earnings than Atossa Genetics. Gain Therapeutics is trading at a lower price-to-earnings ratio than Atossa Genetics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gain Therapeutics$50K1,488.49-$20.16M-$0.58N/A
Atossa GeneticsN/AN/A-$34.77M-$3.21N/A

Gain Therapeutics has a beta of 0.15, suggesting that its stock price is 85% less volatile than the broader market. Comparatively, Atossa Genetics has a beta of 1.25, suggesting that its stock price is 25% more volatile than the broader market.

Gain Therapeutics currently has a consensus target price of $7.50, indicating a potential upside of 329.80%. Atossa Genetics has a consensus target price of $20.33, indicating a potential upside of 729.93%. Given Atossa Genetics' higher possible upside, analysts clearly believe Atossa Genetics is more favorable than Gain Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gain Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.67
Atossa Genetics
2 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.20

Atossa Genetics' return on equity of -84.91% beat Gain Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Gain TherapeuticsN/A -201.44% -136.24%
Atossa Genetics N/A -84.91%-72.36%

Summary

Atossa Genetics beats Gain Therapeutics on 7 of the 13 factors compared between the two stocks.

Get Atossa Genetics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ATOS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ATOS vs. The Competition

Export
MetricAtossa GeneticsMED INSTRUMENTS IndustryMedical SectorNASDAQ Exchange
Market Cap$21.09M$7.18B$6.80B$12.40B
Dividend YieldN/A1.32%2.67%9.39%
P/E Ratio-0.7649.9227.0824.12
Price / SalesN/A50.88516.4792.58
Price / CashN/A26.9126.6847.25
Price / Book0.546.9710.636.23
Net Income-$34.77M$162.27M$3.60B$331.53M
7 Day Performance8.41%-0.98%-1.08%-1.30%
1 Month Performance21.89%-1.98%1.28%-1.40%
1 Year Performance-80.75%5.96%24.71%18.15%

Atossa Genetics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ATOS
Atossa Genetics
2.0329 of 5 stars		$2.45
-1.6%		$20.33
+729.9%		-80.3%$21.09MN/AN/A8
ENTX
Entera Bio
2.2363 of 5 stars		$1.61
-1.8%		$9.00
+459.0%		-2.9%$79.36M$40KN/A20
HRTX
Heron Therapeutics
1.7763 of 5 stars		$0.42
+0.0%		$2.50
+499.5%		-75.1%$78.93M$154.90MN/A300
LFVN
Lifevantage
2.713 of 5 stars		$6.22
+0.4%		$5.00
-19.6%		-51.7%$78.45M$228.53M13.81260
CYPH
Cypherpunk Technologies
1.4488 of 5 stars		$0.73
+4.7%		$0.90
+23.1%		+108.4%$77.85MN/AN/A40

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:ATOS) was last updated on 7/21/2026 by MarketBeat.com Staff.
From Our Partners
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Elon’s new "tollbooth"
The SpaceX IPO was valued at $1.75 trillion. But one analyst says fighting over those shares may be the wrong ...
Weiss Ratings | Sponsoredtc pixel
Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...
Banyan Hill Publishing | Sponsoredtc pixel
Oil is settling in yuan now - here's what that means for gold
Saudi Arabia has terminated its 1974 petrodollar agreement with the United States - the deal that forced every...
Golden Portfolio | Sponsoredtc pixel